- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01243086
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab (STAR)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Age Related Macular Degeneration (ARMD or AMD) is the leading cause of blindness in North America. There are two types of ARMD: dry and wet. Both forms of ARMD cause a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp detail directly in front of you. The wet form is typically more severe and is characterized by the growth and leakage of small blood vessels into the choroid layer of the eye, or the back of the eye. These leaking blood vessels disrupt the structure and function of the eye, causing loss of vision, particularly the sharp vision created by the macula area of the eye.
Upon being accepted to the study, participants will be randomly divided into two groups. One group will receive both ranibizumab and OZURDEX injections and the other group will receive ranibizumab injections and a placebo treatment. To participants in this group, there will be the appearance of a second injection but no actual injection will take place. An individual not connected to the study will assign participants to a group based on a computer-generated system, giving participants at 50% chance of being placed in either group. During the study, participants will not know which group they are in, but will be able to know once the study is finished.
Participants will be asked to come in for an initial assessment to determine their starting visual abilities and medical history. On the next appointment, participants will receive the first treatment injections. They will be asked to come into the clinic every month for six (6) months total for treatment injections and testing. At each appointment, study investigators will take 3-D images of the retina (the back of the eye) using an Optical Coherence Tomography (OCT) imaging device, test eye pressure and determine if there are any signs of infection or inflammation from the injections. On months 1, 3 and 6 investigators will also test vision using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts, contrast sensitivity using a standard contrast sensitivity chart (The Pelli-Robson chart) and take images of the blood vessel growth using a coloured dye (fluorescein) to help see blood vessels. Before every treatment, anesthetic eye drops (proparacaine) will be applied to the eye so participants will not feel the injections. Participants will be given antibiotic eye drops (Zymar®) and will be asked to apply the drops 4 times a day for a few days after the injection to prevent infection.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8G 5E4
- St. Joseph's Healthcare Hamilton Regional Eye Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with wet age-related macular degeneration (ARMD) with evidence of sub-foveal choroidal neo-vascularization (CNV)
- Patients greater than the age 18 years old (male or female)
- Visual acuity must be between 20/40 and 20/320 in the study eye.
Exclusion Criteria:
- Patients with CNV from causes other than ARMD
- Patients having intra-ocular surgery within past 3 months on study eye
- Patients with medically uncontrolled glaucoma
- Patients with prior vitreous/retinal surgery
- Patients with a history of past CNV treatment in study eye
- Patients with other ocular conditions causing vision loss that could confound the analysis of ARMD
- Individuals with a disability preventing accurate vision testing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Ranibizumab
Ranibizumab is the current gold standard treatment for wet age-related macular degeneration.
This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada.
Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
|
Intra-vitreal injections of 0.5mg/0.05
mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Other Names:
|
Active Comparator: Ranibizumab and OZURDEX
Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection.
The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects.
It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.
Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation.
The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
|
OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gains in visual acuity
Time Frame: Baseline and months 1, 2, 3, 4, 5, and 6
|
Gains in visual acuity will be assessed by comparing best corrected visual acuity at each follow up appointment by the standardized vision testing, early treatment diabetic retinopathy study (ETDRS) visual acuity test.
The ETDRS visual acuity test was first developed to effectively evaluate visual changes following panretinal photocoagulation in patients with diabetic retinopathy.
This method of measuring visual acuity was more accurate than previous methods, and thus has become the global standard, especially for clinical trials where it is essential to have utmost accuracy.
|
Baseline and months 1, 2, 3, 4, 5, and 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in intraocular pressure
Time Frame: Baseline and months 1, 2, 3, 4, 5 and 6
|
To be measured by tonometry
|
Baseline and months 1, 2, 3, 4, 5 and 6
|
Rates of re-treatment
Time Frame: Months 1, 2, 3, 4, 5 and 6
|
To be measured by recording each drug administration date
|
Months 1, 2, 3, 4, 5 and 6
|
Rate of vision loss
Time Frame: Baseline and months 1, 2, 3, 4, 5 and 6
|
To be measured by ETDRS visual acuity testing and compared over the course of the study
|
Baseline and months 1, 2, 3, 4, 5 and 6
|
Rate of cataract progression
Time Frame: Baseline and months 1, 2, 3, 4, 5, and 6
|
Measured at each appointment with a slit lamp examination
|
Baseline and months 1, 2, 3, 4, 5, and 6
|
Changes in choroid vessel activity in lesion growth and activity at choroid
Time Frame: Baseline and months 1, 2, 3, 4, 5 and 6
|
The changes in blood vessel lesion growth and activity will be measured by OCT (Ocular Coherence Tomography) and fundus fluorescein angiography to assess choroidal neovascular leakage
|
Baseline and months 1, 2, 3, 4, 5 and 6
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Varun Chaudhary, M.D., FRCSC, McMaster University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Wet Macular Degeneration
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Ranibizumab
Other Study ID Numbers
- STARP2SJHH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wet Macular Degeneration
-
Caregen Co. Ltd.CBCC Global ResearchNot yet recruitingAge-related Wet Macular DegenerationUnited States
-
Sam Chun Dang Pharm. Co. Ltd.CompletedNeovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
-
AbbVieCompletedWet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedExudative Macular Degeneration | Neovascular Age-elated Macular Degeneration (Wet AMD)United States
-
University of IowaRecruitingWet Age-related Macular Degeneration | Exudative Macular DegenerationUnited States
-
University of Illinois at ChicagoStanford University; Bascom Palmer Eye Institute; Illinois Retina AssociatesUnknownMacular Degeneration | Macular Degeneration, Wet | Macular Degeneration, Dry
-
Kapil KapoorCompletedWet Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawnWet Age-related Macular Degeneration (Wet AMD)
-
AbbVieAbbVieEnrolling by invitationGene Therapy | AMD | nAMD | Wet AMD | Neovascular Age-Related Macular Degeneration (nAMD) | wAMDUnited States
-
Sorlandet Hospital HFActive, not recruitingWet Macular DegenerationNorway
Clinical Trials on Ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted